In no uncertain terms, a federal judge in Manhattan dismissed with prejudice an antitrust suit by a Russian drugmaker who accused three rivals of an elaborate conspiracy to keep its biosimilar cancer drugs out of the U.S. market.
*May exclude premium content
Already have an account? Sign In Now
Interested in customizing your subscription with Law.com All Access?
Contact our Sales Professionals at 1-855-808-4530 or send an email to email@example.com to learn more.